Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

NCAM1/FGF module serves as a putative pleuropulmonary blastoma therapeutic target.

Shukrun R, Golan H, Caspi R, Pode-Shakked N, Pleniceanu O, Vax E, Bar-Lev DD, Pri-Chen S, Jacob-Hirsch J, Schiby G, Harari-Steinberg O, Mark-Danieli M, Dekel B, Toren A.

Oncogenesis. 2019 Sep 2;8(9):48. doi: 10.1038/s41389-019-0156-9.

2.

Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation.

Pode-Shakked B, Heimer G, Vilboux T, Marek-Yagel D, Ben-Zeev B, Davids M, Ferreira CR, Philosoph AM, Veber A, Pode-Shakked N, Kenet G, Soudack M, Hoffmann C, Vernitsky H, Safaniev M, Lodzki M, Lahad A, Shouval DS, Levinkopf D, Weiss B, Barg AA, Daka A, Amariglio N, Malicdan MCV, Gahl WA, Anikster Y.

Mol Genet Metab. 2019 Sep - Oct;128(1-2):151-161. doi: 10.1016/j.ymgme.2019.08.003. Epub 2019 Aug 14.

PMID:
31445883
3.

Blastemal NCAM+ALDH1+ Wilms' tumor cancer stem cells correlate with disease progression and poor clinical outcome: A pilot study.

Raved D, Tokatly-Latzer I, Anafi L, Harari-Steinberg O, Barshack I, Dekel B, Pode-Shakked N.

Pathol Res Pract. 2019 Aug;215(8):152491. doi: 10.1016/j.prp.2019.152491. Epub 2019 Jun 10.

PMID:
31202518
4.

BRPF1-associated intellectual disability, ptosis, and facial dysmorphism in a multiplex family.

Pode-Shakked N, Barel O, Pode-Shakked B, Eliyahu A, Singer A, Nayshool O, Kol N, Raas-Rothschild A, Pras E, Shohat M.

Mol Genet Genomic Med. 2019 Jun;7(6):e665. doi: 10.1002/mgg3.665. Epub 2019 Apr 24.

5.

Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia.

Pode-Shakked N, Blau A, Pode-Shakked B, Tiosano D, Weintrob N, Eyal O, Zung A, Levy-Khademi F, Tenenbaum-Rakover Y, Zangen D, Gillis D, Pinhas-Hamiel O, Loewenthal N, de Vries L, Landau Z, Rachmiel M, Abu-Libdeh A, Eliakim A, Strich D, Koren I, German A, Sack J, Almashanu S.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3172-3180. doi: 10.1210/jc.2018-02468.

PMID:
30865229
6.

In Vivo Expansion of Cancer Stemness Affords Novel Cancer Stem Cell Targets: Malignant Rhabdoid Tumor as an Example.

Golan H, Shukrun R, Caspi R, Vax E, Pode-Shakked N, Goldberg S, Pleniceanu O, Bar-Lev DD, Mark-Danieli M, Pri-Chen S, Jacob-Hirsch J, Kanter I, Trink A, Schiby G, Bilik R, Kalisky T, Harari-Steinberg O, Toren A, Dekel B.

Stem Cell Reports. 2018 Sep 11;11(3):795-810. doi: 10.1016/j.stemcr.2018.07.010. Epub 2018 Aug 16.

7.

Geometry of Gene Expression Space of Wilms' Tumors From Human Patients.

Trink A, Kanter I, Pode-Shakked N, Urbach A, Dekel B, Kalisky T.

Neoplasia. 2018 Aug;20(8):871-881. doi: 10.1016/j.neo.2018.06.006. Epub 2018 Jul 18.

8.

Severe fetal hydronephrosis: the added value of associated congenital anomalies of the kidneys and urinary tract (CAKUT) in the prediction of postnatal outcome.

Perlman S, Roitman L, Lotan D, Kivilevitch Z, Pode-Shakked N, Pode-Shakked B, Achiron R, Dekel B, Gilboa Y.

Prenat Diagn. 2018 Feb;38(3):179-183. doi: 10.1002/pd.5206. Epub 2018 Feb 7.

PMID:
29314159
9.

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target.

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Dec;9(12):1763. doi: 10.15252/emmm.201708507. No abstract available.

10.

Wilms Tumor NCAM-Expressing Cancer Stem Cells as Potential Therapeutic Target for Polymeric Nanomedicine.

Markovsky E, Vax E, Ben-Shushan D, Eldar-Boock A, Shukrun R, Yeini E, Barshack I, Caspi R, Harari-Steinberg O, Pode-Shakked N, Dekel B, Satchi-Fainaro R.

Mol Cancer Ther. 2017 Nov;16(11):2462-2472. doi: 10.1158/1535-7163.MCT-17-0184. Epub 2017 Jul 20.

11.

Evidence of In Vitro Preservation of Human Nephrogenesis at the Single-Cell Level.

Pode-Shakked N, Gershon R, Tam G, Omer D, Gnatek Y, Kanter I, Oriel S, Katz G, Harari-Steinberg O, Kalisky T, Dekel B.

Stem Cell Reports. 2017 Jul 11;9(1):279-291. doi: 10.1016/j.stemcr.2017.04.026. Epub 2017 May 25.

12.

Peroxisome proliferator-activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target

Pleniceanu O, Shukrun R, Omer D, Vax E, Kanter I, Dziedzic K, Pode-Shakked N, Mark-Daniei M, Pri-Chen S, Gnatek Y, Alfandary H, Varda-Bloom N, Bar-Lev DD, Bollag N, Shtainfeld R, Armon L, Urbach A, Kalisky T, Nagler A, Harari-Steinberg O, Arbiser JL, Dekel B.

EMBO Mol Med. 2017 Apr;9(4):508-530. doi: 10.15252/emmm.201506111. Erratum in: EMBO Mol Med. 2017 Dec;9(12 ):1763.

13.

Prenatal diagnosis of 17q12 deletion syndrome: from fetal hyperechogenic kidneys to high risk for autism.

Gilboa Y, Perlman S, Pode-Shakked N, Pode-Shakked B, Shrim A, Azaria-Lahav E, Dekel B, Yonath H, Berkenstadt M, Achiron R.

Prenat Diagn. 2016 Nov;36(11):1027-1032. doi: 10.1002/pd.4926. Epub 2016 Oct 25.

PMID:
27634641
14.

Dissecting Stages of Human Kidney Development and Tumorigenesis with Surface Markers Affords Simple Prospective Purification of Nephron Stem Cells.

Pode-Shakked N, Pleniceanu O, Gershon R, Shukrun R, Kanter I, Bucris E, Pode-Shakked B, Tam G, Tam H, Caspi R, Pri-Chen S, Vax E, Katz G, Omer D, Harari-Steinberg O, Kalisky T, Dekel B.

Sci Rep. 2016 Mar 29;6:23562. doi: 10.1038/srep23562.

15.

A novel mutation in the C7orf11 gene causes nonphotosensitive trichothiodystrophy in a multiplex highly consanguineous kindred.

Pode-Shakked B, Marek-Yagel D, Greenberger S, Pode-Shakked N, Pras E, Barzilai A, Yassin S, Sidi Y, Anikster Y.

Eur J Med Genet. 2015 Dec;58(12):685-8. doi: 10.1016/j.ejmg.2015.10.012. Epub 2015 Oct 27.

PMID:
26518168
16.

Wilms' tumor blastemal stem cells dedifferentiate to propagate the tumor bulk.

Shukrun R, Pode-Shakked N, Pleniceanu O, Omer D, Vax E, Peer E, Pri-Chen S, Jacob J, Hu Q, Harari-Steinberg O, Huff V, Dekel B.

Stem Cell Reports. 2014 Jun 26;3(1):24-33. doi: 10.1016/j.stemcr.2014.05.013. eCollection 2014 Jul 8.

17.

Targeted therapy aimed at cancer stem cells: Wilms' tumor as an example.

Shukrun R, Pode Shakked N, Dekel B.

Pediatr Nephrol. 2014 May;29(5):815-23; quiz 821. doi: 10.1007/s00467-013-2501-0. Epub 2013 Jun 13. Review.

PMID:
23760992
18.

The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets.

Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P, Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y, Fridman E, Meir K, Simon A, Magister M, Kaminski N, Goldmacher VS, Harari-Steinberg O, Dekel B.

EMBO Mol Med. 2013 Jan;5(1):18-37. doi: 10.1002/emmm.201201516. Epub 2012 Dec 13.

19.

Familial autosomal recessive renal tubular acidosis: importance of early diagnosis.

Vivante A, Lotan D, Pode-Shakked N, Landau D, Svec P, Nampoothiri S, Verma I, Abu-Libdeh A, Bockenhauer D, Dekel B, Anikster Y.

Nephron Physiol. 2011;119(3):p31-9. doi: 10.1159/000329668. Epub 2011 Aug 18.

PMID:
21849803
20.

Wilms tumor--a renal stem cell malignancy?

Pode-Shakked N, Dekel B.

Pediatr Nephrol. 2011 Sep;26(9):1535-43. doi: 10.1007/s00467-011-1858-1. Epub 2011 Apr 16. Review.

PMID:
21499773
21.

Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.

Pode-Shakked N, Harari-Steinberg O, Haberman-Ziv Y, Rom-Gross E, Bahar S, Omer D, Metsuyanim S, Buzhor E, Jacob-Hirsch J, Goldstein RS, Mark-Danieli M, Dekel B.

Oncogene. 2011 Apr 7;30(14):1664-80. doi: 10.1038/onc.2010.549. Epub 2011 Jan 17.

PMID:
21472018
22.

The transcription factor grainyhead-like 2 regulates the molecular composition of the epithelial apical junctional complex.

Werth M, Walentin K, Aue A, Schönheit J, Wuebken A, Pode-Shakked N, Vilianovitch L, Erdmann B, Dekel B, Bader M, Barasch J, Rosenbauer F, Luft FC, Schmidt-Ott KM.

Development. 2010 Nov;137(22):3835-45. doi: 10.1242/dev.055483.

23.

Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.

Pode-Shakked N, Metsuyanim S, Rom-Gross E, Mor Y, Fridman E, Goldstein I, Amariglio N, Rechavi G, Keshet G, Dekel B.

J Cell Mol Med. 2009 Aug;13(8B):1792-808.

24.

Expression of stem cell markers in the human fetal kidney.

Metsuyanim S, Harari-Steinberg O, Buzhor E, Omer D, Pode-Shakked N, Ben-Hur H, Halperin R, Schneider D, Dekel B.

PLoS One. 2009 Aug 21;4(8):e6709. doi: 10.1371/journal.pone.0006709. Erratum in: PLoS One. 2011;6(3). doi: 10.1371/annotation/5c42ca40-0a01-4e4e-94e3-ccaa2cc54fc6.

25.

Accumulation of malignant renal stem cells is associated with epigenetic changes in normal renal progenitor genes.

Metsuyanim S, Pode-Shakked N, Schmidt-Ott KM, Keshet G, Rechavi G, Blumental D, Dekel B.

Stem Cells. 2008 Jul;26(7):1808-17. doi: 10.1634/stemcells.2007-0322. Epub 2008 May 8.

26.

Schimke immuno-osseous dysplasia: expression of SMARCAL1 in blood and kidney provides novel insight into disease phenotype.

Dekel B, Metsuyanim S, Goldstein N, Pode-Shakked N, Kovalski Y, Cohen Y, Davidovits M, Anikster Y.

Pediatr Res. 2008 Apr;63(4):398-403. doi: 10.1203/PDR.0b013e31816721cc.

PMID:
18356746

Supplemental Content

Loading ...
Support Center